Please login to the form below

Not currently logged in
Email:
Password:

CHMP 2019

This page shows the latest CHMP 2019 news and features for those working in and with pharma, biotech and healthcare.

CHMP backs Lynparza in breast cancer, Dupixent in asthma

CHMP backs Lynparza in breast cancer, Dupixent in asthma

PARP inhibitor Lynparza (olaparib) – already making big headway in ovarian cancer – was given a positive opinion by the CHMP for BRCA-mutated, HER2-negative breast cancer, around a year after the ... Two rare diseases are on track to get their new

Latest news

  • Shire’s angioedema drug Takhzyro recommended in Europe Shire’s angioedema drug Takhzyro recommended in Europe

    The European Medicines Agency's CHMP committee has recommended Shire’s Takhzyro (lanadelumab), a new rare disease treatment which has blockbuster potential. ... Lanadelumab had been granted accelerated assessment by the EMA, which cut the evaluation

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics